Clinical Consultations™: Evolving Paradigms for the Management of Chronic Kidney Disease and Cardiovascular Comorbidities

Release Date: April 19, 2022

Expiration Date: April 19, 2023

Activity Overview

Type 2 diabetes (T2D) is a leading cause of morbidity and mortality worldwide, and it is estimated that 9.3% of the global population is affected by this condition. Diabetic kidney disease (DKD) is a disease multiplier that increases the risk of stroke, cardiac and vascular disease. It affects up to 40% of patients with diabetes during their lifespan, exposing them to a 3-fold higher risk of cardiovascular (CV) death compared with those with diabetes alone. In fact, patients with DKD are far more likely to die from cardiovascular disease (CVD) than to progress to end-stage renal disease (ESRD). Not surprisingly, this burden of complications and comorbidity translates to poor quality of life (QoL) and substantially higher health care resource utilization and costs.

During this Clinical Consultations™ program, 2 expert faculty discuss the importance of screening patients with chronic kidney disease (CKD) for comorbidities and treating them early. They also discuss the treatment options available among both current and emerging classes of therapies and across different clinical subspecialties.

Target Audience

This educational activity is directed toward nephrologists, cardiologists, primary care providers, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with CKD.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Summarize current guideline recommendations regarding testing for CKD in at-risk patients with T2D
• Discuss clinical trial evidence regarding therapies for patients with CKD and CV comorbidities
• Develop treatment plans for patients with CKD and CV comorbidities based on current evidence and patient presentation

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.